Biotech Finally Breaks Through the Wall
Research - Biotech is finally breaking out to new all-time highs, and you’ll be hard-pressed to find much red on your watch-list. We wrote about the current … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Synergy Exceeds Expectations in Latest Study
Research - Synergy Pharmaceuticals (SGYP) reported positive data from the first of two phase 3 trials for its constipation drug plecanatide on Wednesday.
Read now
Takeaways From bluebird’s Latest Presentation
Research - This weekend, bluebird bio (BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) in the HBG-205 … Continue Reading
Read now
A Roundup of Last Week in Healthcare
Recap - If you were hiding under a rock this week, three events stood out in the world of biotech investing. On Tuesday and Wednesday, a panel … Continue Reading
Read now
FDA Panel Says “Meh” to Cholesterol-Lowering as a Surrogate Endpoint
Research - The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted on Tuesday to approve Regeneron (REGN) and Sanofi’s (SNY) cholesterol-lowering antibody, Praluent (alirocumab) – but with some caveats.
Premium
Sage’s Depression Results Put Eyes on Marinus
Research - Shares of Sage Therapeutics (SAGE) climbed higher on Tuesday with the first glimpse at SAGE-547’s potential in post-partum depression. And with it went Marinus Pharmaceuticals … Continue Reading
Read now
Finally, QLT Inc Makes a Move
Research - QLT Inc. (QLTI) finally made the move we had been waiting for – although it's perhaps not the move we had been hoping for.
Premium